Rakesh Jain, MD, MPH, RD

psych congress family and friends podcast

Podcasts

01/06/2025

Join Dr Rakesh Jain and Dr Craig Chepke for a discussion of feelings surrounding the recent passing of Dr Vladimir Maletic leads to an exploration of a topic near and dear to Dr Maletic's heart—the role of norepinephrine in clinical practice.

Join Dr Rakesh Jain and Dr Craig...

01/06/2025

Psych Congress Network

Podcasts

Welcome to Psych Congress Family & Friends Hosted by Rakesh Jain and Craig Chepke

01/06/2025

Rakesh Jain , MD, MPH, RD;

Craig Chepke , MD, DFAPA;

Introducing our new psychiatry and psychopharmacology podcast aimed at enhancing your clinical practice in an approachable and heartfelt way, hosted by Rakesh Jain, MD, MPH, and Craig Chepke, MD, DFAPA. Subscribe now!

Introducing our new psychiatry...

01/06/2025

Psych Congress Network

Clinical Pearls

How can APPs best work with supervising doctors in TRD and MDD treatment?

12/05/2024

Rakesh Jain , MD, MPH, RD;

Brooke Kempf , MSN, PMHNP-BC;

Kempf and Jain continue their discussion on depression treatment to discuss how APPs and MDs can collaborate to treat patients together.

Kempf and Jain continue their...

12/05/2024

Psych Congress NP Institute

Quiz

What percentage of patients with TRD may have bipolar depression?

11/13/2024

Rakesh Jain , MD, MPH, RD;

Brooke Kempf , MSN, PMHNP-BC;

Time to test your knowledge with a pop quiz!

Time to test your knowledge with...

11/13/2024

Psych Congress NP Institute

Clinical Pearls

Using Comprehensive Management of TRD to Improve Patient Outcomes

11/05/2024

Brooke Kempf , MSN, PMHNP-BC;

Rakesh Jain , MD, MPH, RD;

Discover why careful diagnosis is crucial, how to leverage glutamatergic therapies, and the role of holistic methods like exercise and psychotherapy in improving patient outcomes.

Discover why careful diagnosis...

11/05/2024

Psych Congress NP Institute

The Rapid Mood Screener: A Novel and Pragmatic Screener Tool for Bipolar I Disorder

Introduction: Depressive episodes/symptoms of bipolar I disorder (BPD-I) are commonly misdiagnosed as major depressive disorder (MDD). We developed the novel and pragmatic Rapid Mood Scre...

Patrick Gillard , PharmD, MS;

Amanda Harrington , PhD;

Kate Sullivan , APN, RN;

Lauren Nelson , PhD;

Roger McIntyre , MD, FRCPC;

Susan McElroy , MD;

Rakesh Jain , MD, MPH, RD;

Charles Brendan Montano , MD;

Mehul Patel , MD, PharmD;

T. Michelle Brown , PhD;

Prakash M. Masand , MD;

10/08/2020

Videos

Approaching Psychedelics for Depression With Both Caution and Optimism

02/06/2024

Rakesh Jain , MD, MPH, RD;

Rakesh Jain, MD, MPH, explains when clinicians may need to be more cautious when weighing the benefits of psychedelic therapy for depression.

Rakesh Jain, MD, MPH, explains...

02/06/2024

Psych Congress Network

Impact of Lemborexant on Patient-Reported Insomnia-Related Worry/Distress and Interference With Daily Functioning Over 6 Months: Results From SUNRISE-2

INTRODUCTION: The insomnia severity index (ISI) is a self-report instrument that evaluates perception of insomnia severity. In Study 303 (SUNRISE-2), lemborexant (LEM) showed greater red...

Rakesh Jain , MD, MPH, RD;

Jane Yardley , PhD;

Kate Pinner , MSc;

Manoj Malhotra , MD;

Margaret Moline , PhD;

Norman Atkins Jr., MBA, PhD;

Craig Chepke , MD, DFAPA;

10/08/2020

Effect of Lemborexant Treatment Across 12 Months on Fatigue Severity and Sleep Outcomes in Subjects With Clinically Significant Fatigue at Baseline

Introduction: The Fatigue Severity Scale (FSS) assesses impact of fatigue on patients’ lives. Lemborexant (LEM) efficacy was examined in the subgroup of subjects with baseline FSS total s...

Norman Atkins Jr., MBA, PhD;

Craig Chepke , MD, DFAPA;

Rakesh Jain , MD, MPH, RD;

Jane Yardley , PhD;

Manoj Malhotra , MD;

Kate Pinner , MSc;

Margaret Moline , PhD;

10/08/2020

Efficacy of Cariprazine in Patient Subgroups: Post Hoc Analysis of 3 Randomized, Placebo-Controlled Trials in Patients With Bipolar Depression

Introduction: Cariprazine is a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat bipolar depression. The efficacy of cariprazine in patients wit...

Vladimir Maletic , MD;

Lakshmi Yatham , MBBS, FRCPC, MRCP, MBA;

Rakesh Jain , MD, MPH, RD;

Willie Earley , MD;

Mehul Patel , MD, PharmD;

Mauricio Tohen , MD, DrPH, MBA;

10/08/2020